Allurion Technologies Inc. Stock

Equities

ALUR

US02008G1022

Software

Market Closed - Nyse 04:00:02 2024-05-01 pm EDT 5-day change 1st Jan Change
2.35 USD +16.92% Intraday chart for Allurion Technologies Inc. +28.42% -37.17%
Sales 2024 * 62.05M Sales 2025 * 77.85M Capitalization 113M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.81 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 503
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+16.92%
1 week+28.42%
Current month+16.92%
1 month+38.24%
3 months-20.61%
6 months-45.48%
Current year-37.17%
More quotes
1 week
1.86
Extreme 1.86
2.35
1 month
1.70
Extreme 1.7
3.95
Current year
1.56
Extreme 1.56
3.95
1 year
1.56
Extreme 1.56
9.00
3 years
1.56
Extreme 1.56
9.00
5 years
1.56
Extreme 1.56
9.00
10 years
1.56
Extreme 1.56
9.00
More quotes
Date Price Change Volume
24-05-01 2.35 +16.92% 210,672
24-04-30 2.01 0.00% 32,186
24-04-29 2.01 +4.69% 88,137
24-04-26 1.92 +3.78% 43,639
24-04-25 1.85 +1.09% 33,116

Delayed Quote Nyse, May 01, 2024 at 04:00 pm EDT

More quotes
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion Connected Scale and Allurion Health Tracker. Allurion Connected Scale offers a complete weight tracking experience, allowing users to monitor their weight, body mass index (BMI) and body composition. Allurion Health Tracker tracks steps, exercise and sleep. Allurion Virtual Care Suite is available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan, which includes gastric balloon, surgical and medical or nutritional. Its Allurion Programme is offered in six months, 12 months and 12-18 months program.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.35 USD
Average target price
5 USD
Spread / Average Target
+112.77%
Consensus

Quarterly revenue - Rate of surprise